Facebook
Twitter
LinkedIn
Forward
Understanding the Role of Lp(a) as a CV Risk Marker to Therapeutic Target in the Prevention of ASCVD
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enhance CVD risk prediction in certain patients. As emerging CVD risk factors, including Lp(a), are increasingly recognized as a target for therapy in the prevention and treatment of ASCVD, clinicians should be aware of the therapeutic advances in this field.
In this activity, experts evaluate the effectiveness and safety of these new approaches, along with current Lp(a) management strategies and patient care practices. The content is structured into an interactive, online compendium divided into chapters, making it easy to digest. Additionally, the compendium is enriched with supplementary resources and recommended readings for further exploration.
Target Audience
US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), sleep specialists, registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
Learning Objectives
After completing this activity, the participant should be better able to:
- Review the role of Lp(a) as a key player in the development and progression of ASCVD.
- Identify patients who would benefit from Lp(a) screening according to the current evidence and guidelines.
- Evaluate the latest evidence about current and emerging therapies that lower Lp(a) and address residual ASCVD risk.
Additional Information
Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC
Director of Atherosclerosis and Lipoprotein-apheresis Center Pharmacology
The University of Kansas Health System
Kansas City, KS
Christie M. Ballantyne, MD
Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Director of Women’s Cardiovascular Health Research
Director of IMPACT Center at Johns Hopkins
Associate Director of Preventive Cardiology
Associate Professor of Medicine and Epidemiology
Division of Cardiology
Johns Hopkins University School of Medicine
Baltimore, MD
ESTIMATED TIME TO COMPLETE ACTIVITY
1.5 hours
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-24-130-H01-P. Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
DIETITIAN CONTINUING EDUCATION
This program offers 1.5 CPEUs for dietitians.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.5 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from June 12, 2024 through June 12, 2025.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org. For additional information about the accreditation of this activity, please visit https://partnersed.com
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
DISCLOSURES
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Moriarty, faculty for this educational activity, discloses the following:
- Research, Consultant: Regeneron, Amgen, Kaneka
- Research, Consultant, Executive Committee: Esperion
- Research, Advisory Board: Novartis, Vascular Health Foundation
- Research: Ionis, FH Foundation, Merck
Dr. Ballantyne, faculty for this educational activity, discloses the following:
- Grant/Research Support- All significant. (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, AHA, ADA
- Consultant- 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken*, Esperion, Genentech, Gilead, Illumina, Ionis, Matinas BioPharma Inc, Merck, New Amsterdam*, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic
Dr. Michos, faculty for this educational activity, discloses the following:
- Consultant, Advisor, Speaker: AstraZeneca, Amarin, Amgen, Boehringer Ingelheim, Esperion, Edwards Life Science, Medtronic, Novartis, Novo Nordisk, Pfizer
- Independent Contractor: Bayer
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 CDE
- 1.50 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.